STAT+: Pharmalittle: We’re reading about an AbbVie deal for a psychedelic, Lilly obesity pill trial results, and more
AbbVie agreed to pay up to $1.2 billion to buy Gilgamesh Pharmaceuticals’ investigational psychedelic drug to treat major depression